ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: cancer

Checkpoint Inhibitors May Be Retried after Immune Adverse Event, with Close Monitoring

Marilynn Larkin  |  

NEW YORK (Reuters Health)—After an immune-related adverse event, the risk-reward ratio for an anti-PD-1 (anti-programmed death-1) or anti-PD-L1 (anti-programmed death ligand-1) rechallenge seems to be acceptable if patients are closely monitored, researchers say. “The immune checkpoint inhibitors anti-PD-1 and anti-PD-L1 have proven efficacy in the treatment of many cancers, but patients may experience immune-related adverse…

The ACR’s & EULAR’s Gout Guidelines Include Treatment Approaches

  |  

SNOWMASS VILLAGE, COLO.—The 2019 ACR Winter Rheumatology Symposium featured a session on gout. Despite a good understanding of its pathogenesis and the many effective therapies to treat it, gout remains a major public health problem in the U.S. Ann K. Rosenthal, MD, Will and Cava Ross professor of medicine and chief of the Division of…

Prevent Osteoporotic Fractures with a Fracture Liaison Service

Micah Yu, MD, Anna Lafian, DO, & Christina Downey, MD  |  

Imagine leaving the hospital after suffering a heart attack without being treated for hypertension or being started on a beta blocker. What would we think of the hospital where patients are never educated about the relationship between treating hypertension and reducing myocardial infarction and stroke risk? Unfortunately, this happens every day with osteoporosis and fractures…

The Little-Known (But Not Uncommon) SSc-Lupus Overlap Syndrome

  |  

What happens when systemic sclerosis (SSc) overlaps with other systemic autoimmune rheumatic diseases? Patients with either diffuse cutaneous or limited cutaneous SSc sometimes develop systemic lupus erythematosus (SLE) as well. A new, large cohort study published in the Journal of Rheumatology reveals details on the epidemiology, clinical signs and survival data of SSc-SLE overlap syndrome.1…

MicroOne / shutterstock.com

Rheumatology Drugs at a Glance, Part 2: Psoriasis

Mary Choy, PharmD, BCGP, FASHP  |  

Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

At Vasculitis Conference, Patients Share Hope, Humor & Hardships

Bryn Nelson, PhD  |  

SEATTLE—At the first regional vasculitis patient conference ever held in the Pacific Northwest, a panoramic view of Mt. Rainier on a clear January morning set the tone for a day of optimistic talks about recent successes against the various forms of blood vessel inflammation. One attendee at the Jan. 12 conference, sponsored by the Vasculitis…

Women Diagnosed Years Later than Men for Same Diseases

Tamara Mathias  |  

(Reuters Health)—For a wide range of diseases, diagnosis comes later in life for women than for men, according to a large Danish study. Researchers don’t know whether the later diagnoses are due to genetics, the environment, possible biases in the healthcare system—or some combination of reasons. The study of health data from 6.9 million Danish…

Osteoporosis Experts Discuss Bisphosphonates, Chronic Kidney Disease

  |  

CHICAGO—The osteoporosis session at the 2018 ACR/ARHP Annual Meeting opened with a discussion by Kenneth Saag, MD, MSc, professor of medicine at the University of Alabama, Birmingham, in which he highlighted adverse events associated with osteoporosis medications. Dr. Saag began his presentation by emphasizing that, above all, the audience should keep in mind that the…